This finding is not only in contrast to Cracolici et al. [16], who reported a 5% mutation rate in atypical follicular adenomas and linked ATM mutations with high-grade or anaplastic features, but it also suggests a potential personalized therapeutic strategy, as tumors with DNA repair deficiencies may be susceptible to PARP inhibitors. This evidence concerns the gene ATM and follicular thyroid adenoma.